Details of the Drug

General Information of Drug (ID: DMRTSGP)

Drug Name

Amiloride

Synonyms

Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker)

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1], [2]

Therapeutic Class

Diuretics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

229.63

Topological Polar Surface Area (xlogp)

-0.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly absorbed following oral administration [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Elimination: 49% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 9 hours [5]
Metabolism: The drug is not metabolised [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.47285 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 50 mg/mL [4]

Chemical Identifiers

Formula: C6H8ClN7O
IUPAC Name: 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
Canonical SMILES: C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
InChI: InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)
InChIKey: XSDQTOBWRPYKKA-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 16231
ChEBI ID: CHEBI:2639
CAS Number: 2609-46-3
DrugBank ID: DB00594
TTD ID: D0I0RJ
VARIDT ID: DR00207
ACDINA ID: D00029

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acid-sensing ion channel 1 (ASIC1)	TTRJYB6	ASIC1_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[8]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amiloride

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eplerenone	DMF0NQR	Major	Increased risk of hyperkalemia by the combination of Amiloride and Eplerenone.	Heart failure [BD10-BD1Z]	[29]
Digitoxin	DMWVIGP	Moderate	Increased risk of hypomagnesemia by the combination of Amiloride and Digitoxin.	Heart failure [BD10-BD1Z]	[30]
-----------

Coadministration of a Drug Treating the Disease Different from Amiloride (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Amiloride and Linezolid.	Bacterial infection [1A00-1C4Z]	[31]
Amoxicillin	DMUYNEI	Minor	Altered absorption of Amiloride caused by Amoxicillin.	Bacterial infection [1A00-1C4Z]	[32]
Pentosan polysulfate	DM2HRKE	Moderate	Increased risk of hyperkalemia by the combination of Amiloride and Pentosan polysulfate.	Chronic pain [MG30]	[33]
Phenylbutazone	DMAYL0T	Moderate	Antagonize the effect of Amiloride when combined with Phenylbutazone.	Chronic pain [MG30]	[34]
Ketoprofen	DMRKXPT	Moderate	Antagonize the effect of Amiloride when combined with Ketoprofen.	Chronic pain [MG30]	[34]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Levomilnacipran.	Chronic pain [MG30]	[35]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Amiloride and Olopatadine.	Conjunctiva disorder [9A60]	[36]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Amiloride and Drospirenone.	Contraceptive management [QA21]	[37]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Amiloride and Ardeparin.	Coronary thrombosis [BA43]	[38]
Danaparoid	DM6CLBN	Moderate	Increased risk of hyperkalemia by the combination of Amiloride and Danaparoid.	Deep vein thrombosis [BD71]	[38]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Sertraline.	Depression [6A70-6A7Z]	[35]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Vilazodone.	Depression [6A70-6A7Z]	[35]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Paroxetine.	Depression [6A70-6A7Z]	[35]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Amiloride and Selegiline.	Depression [6A70-6A7Z]	[31]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Vortioxetine.	Depression [6A70-6A7Z]	[35]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Amiloride and Isocarboxazid.	Depression [6A70-6A7Z]	[31]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Milnacipran.	Depression [6A70-6A7Z]	[35]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Escitalopram.	Depression [6A70-6A7Z]	[35]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Amiloride and Tranylcypromine.	Depression [6A70-6A7Z]	[31]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Amiloride and OPC-34712.	Depression [6A70-6A7Z]	[39]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Amiloride and Phenelzine.	Depression [6A70-6A7Z]	[31]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[40]
Mefenamic acid	DMK7HFI	Moderate	Antagonize the effect of Amiloride when combined with Mefenamic acid.	Female pelvic pain [GA34]	[34]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Amiloride and Procarbazine.	Hodgkin lymphoma [2B30]	[31]
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Amiloride and Eprosartan.	Hypertension [BA00-BA04]	[41]
Aliskiren	DM1BV7W	Moderate	Increased risk of hyperkalemia by the combination of Amiloride and Aliskiren.	Hypertension [BA00-BA04]	[42]
Moexipril	DM26E4B	Major	Increased risk of hyperkalemia by the combination of Amiloride and Moexipril.	Hypertension [BA00-BA04]	[43]
Captopril	DM458UM	Major	Increased risk of hyperkalemia by the combination of Amiloride and Captopril.	Hypertension [BA00-BA04]	[43]
Losartan	DM72JXH	Major	Increased risk of hyperkalemia by the combination of Amiloride and Losartan.	Hypertension [BA00-BA04]	[41]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Amiloride and TAK-491.	Hypertension [BA00-BA04]	[41]
Perindopril	DMOPZDT	Major	Increased risk of hyperkalemia by the combination of Amiloride and Perindopril.	Hypertension [BA00-BA04]	[43]
Quinapril	DMR8H31	Major	Increased risk of hyperkalemia by the combination of Amiloride and Quinapril.	Hypertension [BA00-BA04]	[43]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Amiloride and Telmisartan.	Hypertension [BA00-BA04]	[41]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Amiloride and Irbesartan.	Hypertension [BA00-BA04]	[41]
Lisinopril	DMUOK4C	Major	Increased risk of hyperkalemia by the combination of Amiloride and Lisinopril.	Hypertension [BA00-BA04]	[43]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Amiloride and Potassium chloride.	Hypo-kalaemia [5C77]	[44]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Amiloride and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[45]
Meclofenamic acid	DM05FXR	Moderate	Antagonize the effect of Amiloride when combined with Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[34]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Amiloride and Propiomazine.	Insomnia [7A00-7A0Z]	[39]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Amiloride and ITI-007.	Insomnia [7A00-7A0Z]	[39]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Amiloride and Ozanimod.	Multiple sclerosis [8A40]	[31]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Amiloride and Promethazine.	Nausea/vomiting [MD90]	[39]
Sibutramine	DMFJTDI	Moderate	Increased risk of hyponatremia by the combination of Amiloride and Sibutramine.	Obesity [5B80-5B81]	[35]
Naproxen	DMZ5RGV	Moderate	Antagonize the effect of Amiloride when combined with Naproxen.	Osteoarthritis [FA00-FA05]	[34]
Etodolac	DM6WJO9	Moderate	Antagonize the effect of Amiloride when combined with Etodolac.	Pain [MG30-MG3Z]	[34]
Diflunisal	DM7EN8I	Moderate	Antagonize the effect of Amiloride when combined with Diflunisal.	Pain [MG30-MG3Z]	[34]
Ibuprofen	DM8VCBE	Moderate	Antagonize the effect of Amiloride when combined with Ibuprofen.	Pain [MG30-MG3Z]	[34]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Amiloride and Safinamide.	Parkinsonism [8A00]	[31]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Amiloride and Rasagiline.	Parkinsonism [8A00]	[31]
Bromfenac	DMKB79O	Moderate	Antagonize the effect of Amiloride when combined with Bromfenac.	Postoperative inflammation [1A00-CA43]	[34]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Amiloride and Levomepromazine.	Psychotic disorder [6A20-6A25]	[39]
Meloxicam	DM2AR7L	Moderate	Antagonize the effect of Amiloride when combined with Meloxicam.	Rheumatoid arthritis [FA20]	[34]
Sulindac	DM2QHZU	Moderate	Antagonize the effect of Amiloride when combined with Sulindac.	Rheumatoid arthritis [FA20]	[34]
Oxaprozin	DM9UB0P	Moderate	Antagonize the effect of Amiloride when combined with Oxaprozin.	Rheumatoid arthritis [FA20]	[34]
Flurbiprofen	DMGN4BY	Moderate	Antagonize the effect of Amiloride when combined with Flurbiprofen.	Rheumatoid arthritis [FA20]	[34]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Amiloride and Quetiapine.	Schizophrenia [6A20]	[39]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Amiloride and Mesoridazine.	Schizophrenia [6A20]	[39]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Amiloride and Thioridazine.	Schizophrenia [6A20]	[39]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Amiloride and Aripiprazole.	Schizophrenia [6A20]	[39]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Amiloride and Iloperidone.	Schizophrenia [6A20]	[39]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Amiloride and Paliperidone.	Schizophrenia [6A20]	[39]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Amiloride and Perphenazine.	Schizophrenia [6A20]	[39]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Amiloride and Molindone.	Schizophrenia [6A20]	[39]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Amiloride and Thiothixene.	Schizophrenia [6A20]	[39]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Amiloride and Trifluoperazine.	Schizophrenia [6A20]	[39]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Amiloride and Risperidone.	Schizophrenia [6A20]	[39]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Amiloride and Amisulpride.	Schizophrenia [6A20]	[39]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Amiloride and Asenapine.	Schizophrenia [6A20]	[39]
Tacrolimus	DMZ7XNQ	Major	Increased risk of hyperkalemia by the combination of Amiloride and Tacrolimus.	Transplant rejection [NE84]	[46]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Amiloride and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[39]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Amiloride and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[47]
-----------


⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Amiloride Hydrochloride 5mg tablet	5mg	Tablet	Oral
Amiloride 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2421).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070346.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
9	Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol. 2006 Jun;290(6):C1521-31.
10	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
11	Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
12	Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
13	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
14	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
15	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
16	The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
17	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
18	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
19	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
20	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
21	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
22	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
23	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
24	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
25	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
26	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
27	ClinicalTrials.gov (NCT01449487) Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid. U.S. National Institutes of Health.
28	Challenges in analgesic drug development. Clin Pharmacol Ther. 2009 Oct;86(4):447-50.
29	Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58. [PMID: 16373465]
30	Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
31	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
32	Westphal JF, Jehl F, Brogard JM, Carbon C "Amoxicillin intestinal absorption reduction by amiloride: possible role of the na+-h+ exchanger." Clin Pharmacol Ther 57 (1995): 257-64. [PMID: 7697943]
33	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
34	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
35	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
36	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
37	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
38	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
39	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
40	Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
41	Product Information. Midamor (amiloride). Merck & Co, Inc, West Point, PA.
42	Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
43	Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
44	McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970): 58-70. [PMID: 5410663]
45	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
46	Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
47	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.